Epigenomics AG (EPGNF)
USD 0.79
(0.0%)
USD 0.79
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 11.88 Million EUR | 2199.56% |
| 2022 | 517 Thousand EUR | 40.11% |
| 2021 | 369 Thousand EUR | -19.78% |
| 2020 | 460 Thousand EUR | -34.0% |
| 2019 | 697 Thousand EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| 2016 | - EUR | 0.0% |
| 2015 | - EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | -100.0% |
| 2009 | 9000.00 EUR | -76.32% |
| 2008 | 38 Thousand EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | -100.0% |
| 2005 | 4000.00 EUR | -90.24% |
| 2004 | 41 Thousand EUR | 173.33% |
| 2003 | 15 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 124 Thousand EUR | -32.61% |
| 2023 Q1 | 184 Thousand EUR | -64.41% |
| 2023 Q3 | 11.88 Million EUR | 9487.68% |
| 2023 FY | 11.88 Million EUR | 2199.56% |
| 2023 Q4 | 11.88 Million EUR | 0.0% |
| 2022 Q2 | 692 Thousand EUR | -4.95% |
| 2022 Q3 | 629 Thousand EUR | -9.1% |
| 2022 Q4 | 517 Thousand EUR | -17.81% |
| 2022 FY | 517 Thousand EUR | 40.11% |
| 2022 Q1 | 728 Thousand EUR | 97.29% |
| 2021 FY | 369 Thousand EUR | -19.78% |
| 2021 Q4 | 369 Thousand EUR | -6.11% |
| 2021 Q2 | 416 Thousand EUR | -5.02% |
| 2021 Q3 | 393 Thousand EUR | -5.53% |
| 2021 Q1 | 438 Thousand EUR | -4.78% |
| 2020 Q2 | 581 Thousand EUR | -9.5% |
| 2020 Q1 | 642 Thousand EUR | -7.89% |
| 2020 Q4 | 460 Thousand EUR | -11.37% |
| 2020 FY | 460 Thousand EUR | -34.0% |
| 2020 Q3 | 519 Thousand EUR | -10.67% |
| 2019 Q3 | 758 Thousand EUR | -5.72% |
| 2019 FY | 697 Thousand EUR | 0.0% |
| 2019 Q2 | 804 Thousand EUR | 34.22% |
| 2019 Q1 | 599 Thousand EUR | 0.0% |
| 2019 Q4 | 697 Thousand EUR | -8.05% |
| 2018 FY | - EUR | 0.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q1 | - EUR | 0.0% |
| 2018 Q3 | - EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| 2017 Q4 | - EUR | 0.0% |
| 2017 Q3 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 Q1 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 FY | - EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q3 | - EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 FY | - EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2015 Q3 | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2012 Q3 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q1 | - EUR | 0.0% |
| 2011 Q1 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 FY | - EUR | -100.0% |
| 2010 Q1 | 2000.00 EUR | -77.78% |
| 2010 Q2 | - EUR | -100.0% |
| 2010 Q3 | - EUR | 0.0% |
| 2009 Q4 | 9000.00 EUR | 0.0% |
| 2009 FY | 9000.00 EUR | -76.32% |
| 2008 FY | 38 Thousand EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | -100.0% |
| 2005 FY | 4000.00 EUR | -90.24% |
| 2004 FY | 41 Thousand EUR | 173.33% |
| 2003 FY | 15 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 6000.00 USD | -198045.283% |
| Arrayit Corporation | - USD | -Infinity% |
| Atlantic International Corp. | 1.29 Million USD | -816.269% |
| Biocept, Inc. | 10.37 Million USD | -14.59% |
| Bioqual, Inc. | - USD | -Infinity% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 51.3 Million USD | 76.829% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 61.22 Million USD | 80.582% |
| HTG Molecular Diagnostics, Inc. | 546.32 Thousand USD | -2076.129% |
| iMD Companies, Inc. | 1.1 Million USD | -977.202% |
| IDenta Corp. | 428.17 Thousand USD | -2676.596% |
| Interpace Biosciences, Inc. | 4.24 Million USD | -180.196% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | - USD | -Infinity% |
| Lumos Diagnostics Holdings Limited | - USD | -Infinity% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 278 Thousand USD | -4176.517% |
| NovelStem International Corp. | 3.32 Million USD | -257.599% |
| Optigenex Inc. | 4.42 Million USD | -168.546% |
| PharmChem, Inc. | - USD | -Infinity% |
| Proteome Sciences plc | 1.63 Million USD | -628.922% |
| Response Genetics, Inc | 4.91 Million USD | -141.739% |
| Rennova Health, Inc. | 359.19 Thousand USD | -3209.841% |
| RushNet, Inc. | 4.25 Million USD | -179.577% |
| ScreenPro Security Inc. | 249.05 Thousand USD | -4673.627% |
| Stella Diagnostics Inc. | 798.44 Thousand USD | -1388.991% |
| StageZero Life Sciences Ltd. | 576.38 Thousand USD | -1962.645% |
| Todos Medical Ltd. | 33 Million USD | 63.975% |